-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Legend Biotech, Raises Price Target to $49

Benzinga·06/03/2026 18:42:48
Listen to the news
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $31 to $49.